3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
8
Esophageal Squamous Cell Carcinoma
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Rectal Neoplasms
2
Intestinal Neoplasms
2
Gastrointestinal Neoplasms
2
Gastrointestinal Diseases
2
Esophageal Neoplasms
2
Digestive System Neoplasms
2
Colonic Neoplasms
2
Adenocarcinoma Of Esophagus
2
Rectal Diseases
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Intestinal Diseases
1
Digestive System Diseases
1
Colonic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
27
Cisplatin
24
pembrolizumab
15
durvalumab
12
Fluorouracil
11
Capecitabine
10
Oxaliplatin
9
Leucovorin
8
Bevacizumab
7
Carboplatin
5
Paclitaxel
4
Nivolumab
4
Irinotecan
4
Injections
4
zanidatamab
3
trametinib
3
lenvatinib
3
derazantinib
3
atezolizumab
3
Ramucirumab
3
Docetaxel
3
tremelimumab
2
surufatinib
2
pertuzumab
2
gemcitabine-oxaliplatin regimen
2
envafolimab
2
Trastuzumab
2
S 1 (combination)
2
Itraconazole
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Biliary Tract Neoplasms
×
Levoleucovorin
×
Clear all
NCT06428409
2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled